Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of Venous Leg Ulcers (VALUE)

Trial Profile

A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of Venous Leg Ulcers (VALUE)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EscharEx (Primary)
  • Indications Leg ulcer; Varicose ulcer; Wounds
  • Focus Adverse reactions; Registrational
  • Acronyms VALUE
  • Sponsors MediWound

Most Recent Events

  • 28 Apr 2025 According to a MediWound media release, the company announced it will provide an update on the VALUE Phase III study design and enrollment progress at the Symposium on Advanced Wound Care (SAWC) Spring 2025, taking place April 30-May 3 in Grapevine, Texas.
  • 24 Apr 2025 Planned End Date changed from 1 Oct 2026 to 1 Mar 2027.
  • 24 Apr 2025 Planned primary completion date changed from 1 Oct 2026 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top